Table 3 Comparison of primary hMDS and... | American Society of Hematology

Table 3

Comparison of primary hMDS and AA-derived MDS

Clinical characteristics	Primary hMDS, N = 24	Secondary MDS due to AA, N = 10
Age (y)	56 (16-83)	59 (28-75)
Karyotyping by MC	11	5
Normal	10	5
Abnormal	3	0
No growth
IPSS*
Low risk (IPSS: low to int −1)	2	4
High risk (IPSS: Int −2 and higher)	19	6
Median survival (d)	841 (37-2495)	1360 (797-3185)†, P = .9
		2133 (797-3185)‡, P = .009
Time to progression (range)	234 (28-631)	407 (167-1683), P = .0003

Clinical characteristics	Primary hMDS, N = 24	Secondary MDS due to AA, N = 10
Age (y)	56 (16-83)	59 (28-75)
Karyotyping by MC	11	5
Normal	10	5
Abnormal	3	0
No growth
IPSS*
Low risk (IPSS: low to int −1)	2	4
High risk (IPSS: Int −2 and higher)	19	6
Median survival (d)	841 (37-2495)	1360 (797-3185)†, P = .9
		2133 (797-3185)‡, P = .009
Time to progression (range)	234 (28-631)	407 (167-1683), P = .0003

MDS indicates myelodysplastic syndrome; hMDS, hypocellular MDS; AA, aplastic anemia; IPSS, International Prognostic Scoring System; and MC, metaphase cytogenetics.

In 3 patients, there was no growth in MC hence IPSS not available;

†

from diagnosis of MDS; and

‡

from diagnosis of AA.

View Large

This Feature Is Available To Subscribers Only